Texas Children's Cancer Center, Houston, TX 77030, USA.
Curr Hematol Malig Rep. 2010 Oct;5(4):192-9. doi: 10.1007/s11899-010-0059-5.
Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin's lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor. Optimal treatment for this group remains a challenge. Dose intensification followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for these patients, but the number of children treated using this approach is relatively small and its effectiveness has been difficult to judge. Moreover, the limited experience is insufficient to define the patient most likely to benefit from transplantation. Likewise, the selection of autologous or allogeneic transplantation and the optimal conditioning regimen are debated. We summarize the current experience for stem cell transplantation in childhood NHL and offer our recommendations.
尽管采用强化的儿童非霍奇金淋巴瘤(NHL)初级治疗可实现高治愈率,但复发或难治性疾病患儿的预后仍较差。为该群体提供最佳治疗仍然是一个挑战。在这种情况下,已经使用了剂量强化继之以干细胞移植,这可能为这些患者提供一种治愈性治疗选择,但使用这种方法治疗的儿童数量相对较少,其疗效难以判断。此外,有限的经验不足以确定最有可能从移植中受益的患者。同样,自体或同种异体移植的选择以及最佳的预处理方案也存在争议。我们总结了儿童 NHL 中干细胞移植的当前经验,并提出了我们的建议。